Reportlinker Adds Colorectal and Colon Cancer Therapy Area Pipeline Report

NEW YORK, Nov. 29, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Colorectal and Colon Cancer Therapy Area Pipeline Report

http://www.reportlinker.com/p0192791/Colorectal-and-Colon-Cancer-Therapy-Area-Pipeline-Report.html

The Colorectal and Colon Cancer Therapy Area Pipeline Report contains detailed information on the colorectal and colon cancer drug pipeline. This report provides insight into the pipeline status of colorectal and colon cancer drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics' Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

  • Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.

  • Keep track of your competitors and partners by better understanding their product pipeline.

  • Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.

  • Maintain a critical competitive advantage.

Epidemiology Report

% of Products by Phase of Development

No. of Products by Phase of Development

Marketed Products vs. Pipeline Products

Company Overview - Pipeline Projects

Legend

--Top 5 Companies in Early Stage Colorectal and Colon Cancer Products

--Top 5 Companies in Late Stage Colorectal and Colon Cancer Products

--Top 5 Companies in Marketed Colorectal and Colon Cancer Products

Patent Expirations

Upcoming Milestones

Product Sales

Full Pipeline View

--Product Details : Unknown/Research

--Product Details : Pre Clinical

--Product Details : Phase I

--Product Details : Phase II

--Product Details : Phase III

--Product Details : Pending Approval

--Product Details : Approved

--Product Details : On the Market

News Updates

--Deals & Alliances

--Product Updates

--Regulatory

To order this report:

Therapy Industry: Colorectal and Colon Cancer Therapy Area Pipeline Report

Therapy Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.